Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant for vasomotor symptoms in postmenopausal women (26-week placebo-controlled study)
2020-004908-33Phase 3Completed
- Sponsor
- Bayer Consumer Health
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in menopause comparing Elinzanetant with Placebo (2 arms). Primary endpoint: Change in frequency of moderate to severe hot flashes at Week 4. Started Aug 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
menopause
Beyond the preview
Go deeper on 2020-004908-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004908-33.